Request for sample copy of this report @ http://bit.ly/2FNQ7QE
Global biopharmaceuticals market was valued at US$ 161,851.6 Mn in 2014 and is expected to expand at a CAGR of 9.4% to reach US$ 278,232.9 Mn by 2020. Biopharmaceuticals are medical drugs produced using biotechnology. They are proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) used for therapeutic or in vivo diagnostic purposes, and are produced by means other than direct extraction from a native (non-engineered) biological source.
A biopharmaceutical, also known as a biologic medical product, biological, biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living cells or tissues. Substances that are (nearly) identical to the body's own key signalling proteins. Examples are the blood-production stimulating protein erythropoetin, or the growth-stimulating hormone named (simply) "growth hormone" or biosynthetic human insulin and its analogues.
United States Biopharmaceuticals market competition by top manufacturers/players, with Biopharmaceuticals sales volume, price, revenue Million USD and market share for each manufacturer/player; the top players including, Roche, Pfizer, Amgen, Johnson & Johnson, Eli Lilly, Novartis, AbbVie, Novo Nordisk, SanofiAventis, Merck.